RSVPreF3 OA investigational vaccine

Phase 3Vaccine

RSVPreF3 OA investigational vaccine is one of 4 therapeutic programs targeting Respiratory Syncytial Virus Infections. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Respiratory Syncytial Virus InfectionsCompleted

Respiratory Syncytial Virus InfectionsPhase 3

Completed

Competition

Competitive Landscape

6 competitors in Respiratory Syncytial Virus Infections

#DrugCompanyPhaseTrials

RSVPreF3 OA investigational vaccine

GSK

Phase 3

1 2

S-337395

Shionogi

Phase 2

1 3

AK0529

SShanghai Ark Biopharmaceutical Co., Ltd.

Phase 2

1 4

Ziresovir

SShanghai Ark Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Respiratory Syncytial Virus Infections1 trial

A Phase 3, Randomized, Placebo-controlled, Observer-blind Study in India to Evaluate Immune Response, Reactogenicity and Safety of a Single Intramuscular Dose of RSVPreF3 OA Investigational Vaccine When Administered to Older Adults >=60 Years of Age and Adults 50-59 Years of Age at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease

Completed· GSK logo

GSK·Phase 3·NCT06614725·751 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RSVPreF3 OA investigational vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for RSVPreF3 OA investigational vaccine. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine
Highest Phase: Phase 3[1]
Company: GSK

RSVPreF3 OA investigational vaccine

Status by Indication[2][1]

Competitive Landscape

Trials by Indication[1]

Respiratory Syncytial Virus Infections1 trial

References

Drug Info

Quick Facts

Related News